C
rohn's disease (CD) is a chronic immune-mediated inflammatory bowel disease caused by complex interactions between genetics, environment, and gut microbiota. CD can affect the entire gastrointestinal tract, often leading to significant complications requiring surgery and consequently impairing the quality of life of the patients. 1 Recent evidence shows the importance of achieving mucosal healing (MH), demonstrating its association with long-term symptomatic remission, longer periods of relapse-free disease, and reduction in the frequency of hospitalizations, complications, and surgical resections. Consequently, MH has emerged as a relevant therapeutic endpoint in CD. [2] [3] [4] [5] Nevertheless, there is still no validated definition of what constitutes MH in CD. 6 Routine endoscopic assessment is hampered by its costs, potential risks (perforation, bleeding, and cardiovascular complications due to sedation), and lack of patient compliance. However, more than 2/3 of patients with CD have inflammation involving the small bowel. Unfortunately, some segments of inflamed bowel may not be accessible by endoscopy (e. g., strictures, adhesions, and proximal small bowel). Furthermore, unlike in ulcerative colitis, CD is a transmural disease where progressive inflammation leads to intestinal wall thickening, fibrosis, and penetrating complications. Therefore, inflammatory burden and disease prognosis may not be adequately reflected by only assessing the mucosal layer. Small bowel imaging with magnetic resonance enterography (MRE), computed tomography enterography and ultrasound have been proven to be accurate in assessing disease activity and severity, providing appropriate staging of transmural lesions and extramural complications in CD. [7] [8] [9] [10] [11] Because it is not clear if MH corresponds to healing of the bowel wall layers, transmural healing (TH) has been explored in patients with CD treated with anti-tumor necrosis factor alpha (TNFa). [12] [13] [14] Nevertheless, data regarding the potential role of TH as a long-term prognostic factor are still unavailable. We performed a 2-center retrospective observational study to explore the long-term outcomes of TH, evaluated by MRE and colonoscopy, in patients with CD. The outcomes were assessed after 1 year from the combined endoscopic-radiologic examination and included the following: need for surgery, hospital admission, and therapy escalation.
MATERIALS AND METHODS

Study Design and Patients
This was a retrospective observational study conducted at the Department of Gastroenterology and Hepatology, Santa Maria Hospital, and at the Department of Gastroenterology, Instituto Português de Oncologia de Lisboa. Subjects included in the study had a confirmed diagnosis of CD in accordance with the criteria of the European Crohn and Colitis Association. 15 Patients' demographic details, baseline characteristics, and disease course were retrieved from a prospectively maintained national database of inflammatory bowel disease patients (GEDII, Grupo de Estudos de Doença Inflamatória Intestinal, Portugal). Patients gave formal consent before inclusion in the database. Inclusion criteria of this study were as follows: (1) a confirmed diagnosis of CD, (2) current or past inflammation involving the small bowel, and (3) an MRE and a complete colonoscopy with ileoscopy performed within a 6-month interval. This interval was chosen after a subgroup analysis showed no significant differences between a ,3 and a 3-to 6-month interval in terms of age at evaluation, sex, active smoking, disease location, disease behavior, perianal disease, upper gastrointestinal involvement, previous surgery, therapy, and 1-year outcomes.
Patients with a follow-up of less than 12 months, inflammation restricted to the colon, or in which any of the outcomes was reached between MRE and endoscopic assessment were excluded from the analysis. As the study design required an assessment of the small bowel by endoscopy, patients in whom ileoscopy was not possible were also excluded from the study.
MRE Evaluation
The MRE examinations were performed using the same protocol in both centers. Briefly, the patients were asked to abstain from food and drinks 4 to 6 hours before the procedure. To allow optimal luminal distension, the patient drinks 1.5 L to 2 L of a solution of water and mannitol (2.5%) over a period of 40 to 45 minutes before the examination. This solution acts as a hyperosmolar agent, drawing fluid into the bowel appearing as a low-intensity signal on T1-weighted images and with a highintensity signal on T2-weighted images (biphasic technique). Scanning was performed using a 1.5T MRI scanner (Philips), with a phased-array surface coil in a prone position to reduce peristaltic and respiratory movements while also helping to separate the bowel loops. After the whole small bowel is well distended, the patient is given a routine administration of hyoscine (Buscopan). After the initial axial and coronal T1-and T2-weighted images are obtained, we acquire several sequences including balanced fast field echo with short repetition time (,3 mm/sec) and T2 fast spin echo sequences with and without fat suppression. After intravenous gadolinium-based contrast injection, fat-suppressed 3D T1-weighted breath-hold gradient eco images are obtained with acquisitions at 30, 60, and 90 seconds in coronal orientation and at 110 seconds in axial orientation. All MRE examinations were performed by 2 experienced radiologists and reviewed while blinded to the history and clinical symptoms. Finally, the radiologist classified the MRE results as active or inactive based on the presence of any of the following: abnormal bowel wall thickening (defined has a thickness .3 mm), increased contrast enhancement, and complications (stricture, abscess, or fistulae). In inconclusive cases, fat creeping and comb sign were used as additional features for assessment of disease activity.
Endoscopic Evaluation
Endoscopic examinations were performed by experienced endoscopists or by supervised residents. In nonoperated patients, in accordance with current expert recommendations, disease activity by endoscopy was classified as active or inactive based on the presence of mucosal ulceration (excluding aphthoid lesions). 16 In operated patients, disease activity by endoscopy was classified as active or inactive based on a Rutgeerts score $i2. The Rutgeerts score is commonly used by researchers and clinicians for assessing the risk of postoperative clinical and surgical recurrence. 17 In patients with a history of active disease not approachable by standard colonoscopy, upper endoscopy, capsule endoscopy, or balloon enteroscopy were performed to assess for active or inactive mucosal disease.
Definitions of the Groups According to the Type of Healing
We used the term "transmural healing" as a synonym for complete healing of all the bowel layers (including the mucosa). We defined TH as the presence of both a normal MRE and normal endoscopy. In this study, "mucosal healing" included patients having healing of the mucosal surface, without healing of the other layers. MH was therefore defined as an inactive endoscopy with an active MRE. No healing (NH) incorporated the rest of the cohort and included patients having an active endoscopy, irrespective of the MRE findings.
Study Endpoints
The primary outcomes of this study were the need of surgery, hospital admission, and therapy escalation at 12 months from baseline. Surgeries included any bowel resection associated with CD. Surgeries for perianal complications were not included in this definition. Hospitalization was defined as any admission related to CD activity or to severe side effects associated with therapy. Therapy escalation was defined as the need to start an immunomodulator or biologic, the need to escalate a anti-TNFa (increase dosage or shorten interval of administration), or the need to switch to a different biologic. The baseline assessment was performed from the time of the latest examination (MRE or endoscopy).
Statistical Analysis
Continuous variables were expressed as median (range) and compared using the Mann-Whitney test. Categorical variables were described using frequencies and percentages and compared using the chi-square test. Kaplan-Meier survival curves were used to assess the outcome-free survival for each group and were compared using the log-rank test. Correlation between endoscopy and MRE was performed using Spearman's correlation. Logistic regression was used for univariate and multivariate analyses with stepwise selection to investigate factors associated with any positive outcome at 12 months from baseline. Variables with a significant P level (,0.05) in univariate logistic regression analysis were used in the multivariate logistic analysis. Results were expressed as odds ratio (OR) with 95% confidence interval (CI). The significance level was chosen at 0.05. Statistical analysis was performed using IBM Statistical Package for the Social Sciences (SPSS) v21.0.
RESULTS
General Characteristics and Demographics
We included 214 patients in the analysis, 108 (50.5%) male, with median age at evaluation of 36.8 (16-77) years. The median time between diagnosis and evaluation was 7.4 (0-40.8) years. Seventy-three patients (34.1%) were active smokers, and 87 patients (40.7%) had a previous bowel resection. Twenty-two patients (10.3%) had disease involving the upper gastrointestinal tract: in 12 proximal to the duodenum and in the other 10 extending to the jejunum-ileum.
At the time of evaluation, 117 patients (54.7%) were using thiopurines, 1 patient (0.5%) was using methotrexate, and 40 patients (18.7%) were under anti-TNF therapy. Our patient's characteristics are displayed in Table 1 .
MRE and Endoscopy
The median time between the MRE and endoscopy was 2.3 (0-6) months. MRE showed active inflammation in 162 patients (74.3%) and endoscopy in 132 patients (60.6%). According to the previous results, 33 patients (15.4%) were classified as having TH, 52 patients (24.3%) as having MH, and 129 patients (60.3%) as having NH (Fig. 1 ). There was a low correlation between inflammation assessed by MRE and colonoscopy (Spearman's rho ¼ 0.244, P , 0.001).
Differences Between TH, MH, and NH
There was homogeneity in the demographic and clinical characteristics of the 3 groups, with no significant differences in age at evaluation, sex, active smoking, disease location, disease behavior, perianal disease, upper gastrointestinal involvement, previous surgery, and previous therapy. These results are shown in Table 2 .
Long-term Outcomes According to the Type of Healing
The differences between TH, MH, and NH in respect to the need for surgery, hospital admission, and therapy escalation are presented in Figure 2 . The survival curves for each group according to the former outcomes are shown in Figure 3 .
Surgery
By the end of the study period, surgery was required in 16 patients (11.6%) with NH (12 due to refractory strictures, 2 to penetrating complications, and 2 due to severe refractory disease), in 6 patients (11.5%) with MH (5 due to structuring and 1 due to penetrating complications), and in no patient with TH.
Overall, surgery rates in patients with TH were significantly lower than those in patients with MH (0% versus 11.5%, P ¼ 0.047) and NH (0% versus 11.6%, P ¼ 0.027). Patients with TH presented longer time to surgery than patients with MH (log rank, P ¼ 0.045) and NH (log rank, P ¼ 0.044).
Hospital Admission
Only 1 patient (3.0%) with TH required hospital admission because of infectious complications associated with biologic therapy. However, 9 patients (17.3%) with MH (7 due to stenotic complications, 1 due to penetrating complications, and 1 for infectious complications) and 31 patients (24.0%) with NH (18 due to stenotic complications, 9 for surgery, and 4 due to penetrating complications) required hospitalization.
By the end of the first year of follow-up, the differences in hospital admission between TH and MH (3.0% versus 17.3%, P ¼ 0.044) and NH (3.0% versus 24.0%, P ¼ 0.003) were statistically significant. The time until hospital admission was also longer for patients with TH compared with MH (log rank, P ¼ 0.046) and NH (log-rank P ¼ 0.008).
Therapy Escalation
Seventy patients (54.2%) with NH required therapy escalation, 33 by starting a thiopurine, 44 an anti-TNF (1 switch), and 4 by anti-TNF escalation. Nineteen patients (36.5%) with MH required therapy intensification, 10 by starting a thiopurine and 11 an anti-TNF (2 switchers). Finally, 5 patients (15.2%) with TH required therapy escalation, 5 by starting a thiopurine and 1 an anti-TNF.
Patients with TH required less therapy escalation than patients with MH (15.2% versus 36.5%, P ¼ 0.027) and NH (15.2% versus 54.3%, P , 0.001). Patients with TH also presented a longer time until requiring therapy escalation (log rank P ¼ 0.046 and P , 0.001 for MH and NH, respectively).
Any Outcome
Overall, TH was associated with a lower likelihood of reaching any of the former 3 outcomes (15.2% versus 44.2%, P ¼ 0.005 and 63.6%, P , 0.001, for MH and NH, respectively). Patients with TH took longer to reach any of the 3 studied endpoints (log rank, P ¼ 0.019 and P , 0.001 for MH and NH, respectively).
MRE Findings in Patients with NH
Of the 129 patients included in the NH group (active endoscopy with active or inactive MRE), 107 patients (82.9%) had MRE activity and 22 patients (17.1%) were MRE inactive. Comparing for the major outcomes, patients with MRE remission had lower rates of surgery (0% vs 14.0%, P ¼ 0.05), hospital admission (0% vs 29.9%, P ¼ 0.001), therapy escalation (26.4% versus 57.9%, P ¼ 0.053), and any outcome (36.4% versus 69.2%, P ¼ 0.004).
Prediction of Outcomes
In logistic regression analysis, increasing age at evaluation (OR 0.978 95% CI [0.958-0.998], P ¼ 0.033), obtaining endoscopic remission (OR 0.331 95% CI [0.178-0.614], P , 0.001), and MRE remission (OR 0.270 95% CI [0.130-0.564, P , 0.001]) were independently associated with a lower likelihood of reaching any of the studied outcomes (Table 3) .
DISCUSSION
CD is an idiopathic inflammatory disease that tends to follow a chronic relapsing course eventually leading to complications such as strictures, fistulae, and abscesses. Treating to achieve clinical remission in CD has neither been shown to improve the natural course of disease nor decrease the rate of significant outcomes such as hospitalization and surgery. 18 Several studies and meta-analysis have demonstrated that MH is a strong predictor of long-term steroid-free clinical remission and results in lower rates of hospital admission and CD-related surgery. [2] [3] [4] [5] 19 As previously mentioned, CD has a transmural involvement of the gastrointestinal tract. As such, achieving remission limited to the mucosa may not reflect inflammation and intestinal damage occurring in the other layers of the bowel. Even in patients with endoscopic remission, active inflammation can still be detected by cross-sectional studies. 20, 21 Nevertheless, the prognostic significance of these findings is still largely unknown. In this real-life multicenter study, we looked at the influence of different degrees of healing on the course of the disease as reflected by the need for surgical resection, diseaserelated hospitalizations, and therapy escalation. To our knowledge, this is the first study assessing the long-term outcomes of patients with CD in terms of TH. The results are novel in that we have shown that obtaining transmural remission (irrespective of the therapy used) is associated with a significant decrease in the rates of surgery, hospital admission, and therapy escalation. TH also resulted in better 1-year outcomes than MH. Several papers have demonstrated a growing role for assessment of the course of CD using cross-sectional imaging. TH assessed by MRE has been shown to be an accurate predictor of MH and clinical response. 13, 14 In a prospective multicenter study of patients under steroids or anti-TNF, an improvement in MRE activity at 12 weeks, quantified using the Magnetic Resonance Index of Activity (MaRIA), was as reliable as endoscopy in assessing MH with an overall accuracy of 90%. 14 Several authors have demonstrated that MRE can be useful in monitoring clinical responses to anti-TNF agents. 22 Eder et al 23 demonstrated that TH can be used as a predictor of long-term clinical remission after stopping biologic therapy. The absence of TH was associated with an almost 90% probability of another exacerbation in a short period after anti-TNF discontinuation. Nevertheless, achieving TH may be far from easy. Previous studies using ultrasound and MRE have demonstrated that TH can be achieved in only approximately 25% to 31% of patients treated with anti-TNF-a agents. 13, 23 Although in our study the percentage of patients obtaining TH was considerably lower (15.4%), this may have resulted from a lower use of biologics in our cohort. In fact, one study has shown that MRE healing can occur in up to 44% of patients as early as 2 weeks after anti-TNF therapy. 12 A very interesting observation from this study is the fact that patients without MH (NH group) had a better prognosis when there was no MRE activity, with similar outcomes to patients with TH. Although these results should be interpreted with caution (and reproduced prospectively), they may lead us to question the actual role of MH in CD.
Finally, we found only a mild correlation between MRE activity and colonoscopy activity. Once again, this suggests that MH does not necessarily entail TH. Nevertheless, differences in the methodology used for assessing transmural and endoscopic activity might partially explain these results.
Our study has some noticeable limitations. First, the study was retrospective, which might have introduced potential information bias, and these results should be confirmed in adequate prospective trials. Second, we used a dichotomous definition of TH and MH. Although validated endoscopic and MRE scores do exist, their complexity preclude their routine use in clinical practice. A simple definition of activity/inactivity was considered more useful for this study. Finally, as MRE has only been validated for assessment of the small bowel and colonic evaluation is not endorsed by any international guideline, we restricted our analysis to patients with ileal or ileocolonic location. Therefore, our findings cannot be extrapolated to patients with isolated colonic disease. Nevertheless, we hypothesize that isolated colonic CD may behave more like ulcerative colitis, and therefore MH may be a more relevant target in this subgroup than TH.
In conclusion, our study shows that TH is a strong predictor of sustained clinical benefit in CD and is superior to obtaining only MH. Our data further add to the importance of crosssectional imaging, suggesting that TH might be a better suitable treatment target in CD. 
